Literature DB >> 17306956

2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx.

J-L Roh1, K H Pae, S-H Choi, J S Kim, S Lee, S-B Kim, S Y Nam, S Y Kim.   

Abstract

BACKGROUND: High uptake of 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) is associated with unfavorable results. Pretreatment FDG uptake was evaluated as a predictor of survival and guidance for primary surgery or radiotherapy (RT) in patients with squamous cell carcinoma (SCC) of the larynx and hypopharynx.
MATERIALS AND METHODS: Seventy-nine consecutive patients with newly diagnosed advanced resectable SCC of the larynx and hypopharynx underwent FDG positron emission tomography (PET) before surgical resection plus RT and chemotherapy (surgery group, n=40) or RT with chemotherapy and surgical salvage (RT group, n=39). Age, tumor stage, histological grade, treatment strategy, and standardized uptake value (SUV) were analyzed for association with local control and survival.
RESULTS: Overall local control and survival in the two groups did not differ (P>0.1). In univariate analysis, nodal positivity (P=0.014) and SUV>8.0 (P=0.007) were associated with poorer disease-free survival (DFS). In multivariate analysis, SUV remained an independent determinant of DFS (P=0.014). When patients with SUV>8.0 in the two treatment groups were analyzed separately, those in the surgery group tended to have a higher 3-year DFS than those in the RT group, despite no statistical significance (48% vs. 27%, P=0.085).
CONCLUSIONS: High FDG uptake is associated with poor survival in patients with advanced laryngopharyngeal SCC. Patients with high FDG uptake may be better treated by surgical resection followed by RT and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306956     DOI: 10.1016/j.ejso.2007.01.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  19 in total

1.  Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer.

Authors:  Peter A Paximadis; Michael E Christensen; Greg Dyson; Dev P Kamdar; Ammar Sukari; Ho-Sheng Lin; George H Yoo; Harold E Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

Review 2.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

3.  Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.

Authors:  Karen P Chu; James D Murphy; Trang H La; Trevor E Krakow; Andrei Iagaru; Edward E Graves; Annie Hsu; Peter G Maxim; Billy Loo; Daniel T Chang; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

4.  Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.

Authors:  Chia-Hung Kao; Shih-Chieh Lin; Te-Chun Hsieh; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Ji-An Liang; Chun-Hung Hua; Shang-Wen Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-25       Impact factor: 9.236

5.  Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma.

Authors:  Lorenzo Preda; Giorgio Conte; Luke Bonello; Caterina Giannitto; Laura L Travaini; Sara Raimondi; Paul E Summers; Ansarin Mohssen; Daniela Alterio; Maria Cossu Rocca; Chiara Grana; Francesca Ruju; Massimo Bellomi
Journal:  Eur Radiol       Date:  2016-03-10       Impact factor: 5.315

6.  Pretreatment tumor standardized uptake value as a prognostic factor in primary head and neck squamous cell carcinoma.

Authors:  Baitao Zhang; Fang Nie; Bin Jin; Qinghong Meng; Pin Dong
Journal:  Mol Clin Oncol       Date:  2014-11-21

7.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Authors:  Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

8.  FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Stella Lam; Nishant Agrawal; Harry Quon; Rathan M Subramaniam
Journal:  Imaging Med       Date:  2012-12

9.  Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma.

Authors:  Hidenori Inohara; Keisuke Enomoto; Yoichiro Tomiyama; Ichiro Higuchi; Takehiro Inoue; Jun Hatazawa
Journal:  Mol Imaging Biol       Date:  2009-05-07       Impact factor: 3.488

10.  Prognostic Value of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery.

Authors:  Kyu-Ho Choi; Ie Ryung Yoo; Eun Ji Han; Yeon Sil Kim; Gi Won Kim; Sae Jung Na; Dong-Il Sun; So Lyung Jung; Chan-Kwon Jung; Min-Sik Kim; So-Yeon Lee; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.